Bragar Eagel & Squire, P.C. Announces Class Action Suits Against Cassava Sciences and Amylyx Pharmaceuticals

NEW YORK, Feb. 17, 2024 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a law firm with a reputation for defending shareholder rights, has issued a reminder to investors that class action lawsuits have been initiated on behalf of shareholders of two biopharmaceutical companies: Cassava Sciences, Inc. SAVA and Amylyx Pharmaceuticals, Inc. AMLX. These lawsuits are the result of alleged violations of federal securities laws by the named companies. As legal proceedings progress, the firm is calling for affected investors to get in touch to learn more about their rights and potential claims.

Background on the Class Actions

The announcement follows allegations against Cassava Sciences, Inc. SAVA concerning concerns about the integrity of the scientific data supporting its Alzheimer's treatment. Similarly, Amylyx Pharmaceuticals, Inc. AMLX faces scrutiny over its drug designed to treat a neurodegenerative disease, which has reportedly met with regulatory challenges. These issues have prompted shareholders to seek legal recourse under the claim that they were misled, which potentially inflates the companies' stock prices and damages investors upon correction.

Legal Recourse for Investors

Bragar Eagel & Squire, P.C. encourages investors who have incurred losses due to the actions of Cassava Sciences, Inc. SAVA and Amylyx Pharmaceuticals, Inc. AMLX to make contact with the firm. The deadline for lead plaintiff applications may be forthcoming, and timely action is critical for participation in the lawsuit. Through these class action suits, investors aim to recover their losses and set a precedent for corporate transparency and accountability.

lawsuit, investors, reminder